Josh Krichefski Joins PMG as EMEA President
15.10.2025 13:00:00 CEST | Business Wire | Press Release
PMG, a global independent marketing services and technology company, today announced the appointment of Josh Krichefski to EMEA President, effective October 20th. In this new role, Krichefski will lead the strategy and expansion of PMG’s operations across the region, with a focus on scaling growth and driving excellence in customer delivery. He will oversee all aspects of the EMEA business, including commercial performance, talent development, and the introduction of new capabilities and partnerships aligned to PMG’s global vision. Krichefskiwill be based in PMG’s London office and will partner directly with George Popstefanov, Founder & CEO and Jon Dupuis, Global President.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015978859/en/
Josh Krichefski
Dupuis commented: “Josh’s appointment marks an exciting next chapter in our EMEA growth. With more than two decades of experience in shaping agencies and teams across Europe, Josh brings a deep understanding of both the region holistically and the strategic importance of individual markets. Josh’s leadership style reflects PMG’s values—curiosity, agility, and a relentless focus on transformation. His track record speaks for itself, but it’s his alignment with our people-centric culture and customer-obsessed mindset that makes this such a strong fit. We will partner closely to build on the strong momentum we already have in EMEA, continuing to deliver exceptional outcomes for our customers across the region.”
Krichefski, having most recently served as CEO of GroupM EMEA where he led 17,000 people and oversaw $22 billion in media investment billings across 42 markets, brings three decades of experience in agency leadership and brand transformation across a number of firms, including as Global Chief Operating Officer of EssenceMediacom and CEO of MediaCom in the UK and EMEA.
Krichefski said: "I'm incredibly excited to be joining PMG at such a pivotal moment in its growth journey. What drew me to the business goes beyond its impressive trajectory. PMG sits at the intersection of talent, technology and transformation—built for a marketing landscape that demands agility, speed, and innovation. From the outset, I saw a values-driven business that aligns with my own, putting people and customers at the center, while leaning into a future powered by AI, transparency, real-time decisioning, and connected platforms. It’s that combination of purpose, modernity, and momentum that makes this opportunity so energizing.”
Krichefski’s arrival coincides with significant global expansion for PMG, marked by a 20% year-on-year growth. It also follows a series of high-profile leadership appointments in recent months including: Leah Meranus to SVP Customer Success, Matt Dailey as Head of Analytics & Measurement, EMEA, Chad Stoller as Global Head of Media, and Andrea Terrassa as Chief Operating Officer. These additions reflect PMG’s commitment to shaping the future of marketing and advertising through technology, expertise, innovation, and operational excellence.
PMG’s acquisition of Camelot Strategic Marketing & Media, followed by UK-based RocketMill, and more recently, Momentum Commerce, further expanded its global footprint and retail media capabilities.
As part of its ongoing commitment to advancing the technology and AI foundation of the marketing industry, PMG unveiled Alli Marketplace at this year’s Cannes Lions. This first-of-its-kind media-buying solution is fully integrated into its proprietary Alli operating system. The launch featured 22 initial platform and publisher partners and offers marketers unprecedented control, transparency, and speed through automated, intelligence-driven media investments.
About PMG
PMG is a global independent marketing services and technology company that seeks to unlock potential for people and brands. Driven by shared success, PMG brings together business strategy and transformation, creative, media, and insights, all powered by our proprietary marketing operating system, Alli. With offices in New York, London, Dallas & Fort Worth, Austin, Atlanta, Brighton, Costa Rica, Cleveland, and Dusseldorf, our team is made up of more than 1,000 employees globally, and our work for brands like Apple, CKE Restaurants, Dropbox, Experian, Intuit, Kohler, Sephora, Travelex, and Whole Foods has received top industry recognitions including Cannes Lions and Adweek Media Plan of the Year.
Named The Drum’s 2024 Agency of the Year, Digiday’s 2024 Independent Media Agency of the Year, Ad Age’s 2023 A-List, MediaPost’s 2022 Independent Agency of the Year, and Adweek’s 2021 Breakthrough Media Agency, PMG has grown through commitments to continuous improvement, business integrity, and cultivating dynamic relationships. PMG is proud to be named among Fast Company’s Best Workplaces for Innovators, Best Workplaces for Women, and to be the only company named to Ad Age’s Best Places to Work for 10 years in a row. For more information about PMG, visit www.pmg.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251015978859/en/
Contacts
Media Contact:
Rose Marie Adamo
Global Head of Marketing and Communications
+1 954.260.9358
rosemarie.adamo@pmg.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom